Open AccessInhibitors of interleukin 17A in the treatment of psoriatic arthritis: what's new?
Author(s) -
Т. В. Коротаева
Publication year - 2021
Publication title -
sovremennaâ revmatologiâ
Language(s) - English
Resource type - Journals
eISSN - 2310-158X
pISSN - 1996-7012
DOI - 10.14412/1996-7012-2021-2-106-111
Subject(s) - psoriatic arthritis , medicine , psoriasis , observational study , concomitant , interleukin 17 , dermatology , drug , monoclonal antibody , tumor necrosis factor alpha , immunology , pharmacology , cytokine , antibody
In recent years, highly effective target drugs – inhibitors of interleukin 17A (iIL17A) – monoclonal antibodies, – have been widely used to treat patients with psoriatic arthritis (PsA). The efficacy of iIL-17A in psoriasis, PsA, and axial spondyloarthritis has been proven in large multicenter randomized clinical and observational studies. The accumulated evidence and first direct comparative studies with inhibitors of tumor necrosis factor α (iTNFα) suggest that this class of drugs is becoming one of the key drugs in PsA, and the choice of this therapy is more justified, which is reflected in international recommendations. The 2019 revised EULAR guidelines consider iIL 17 first-line biologics along with iTNF-α, whereas iIL-17A is a drug of choice in patients with significant concomitant skin psoriasis.